Aberrant Expression of Fgl-1 and Lag-3 in Adenomyosis

Wenjing Sun, Xiaoyan Qin, Guangxi Yuan, Na Li, Junhui Liang, Chunyan Li, Changzhong Li, Mingjiang Li, Xingbo Ζhao, Hui Zhang
In: Research Square · 2021 · doi:10.21203/rs.3.rs-263822/v1 · W3134891909
preprint OA: green CC0
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

This study evaluated Fgl-1 and Lag-3 expression in normal and adenomyotic endometrium, finding increased Fgl-1 and more Lag-3 positive T-lymphocytes in adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This study evaluated expression of the immune inhibitory receptor Lag-3 and its ligand Fgl-1 in normal endometrium and in eutopic and ectopic endometrial tissue from patients with adenomyosis using immunohistochemistry and immunofluorescence, with samples collected across proliferative and secretory phases. Fgl-1 expression showed no phase-dependent difference in either normal or adenomyotic endometrium, but was increased in both eutopic and ectopic endometrium of adenomyosis compared with normal endometrium. Lag-3 was almost negative in endometrial glands across groups, while Lag-3–positive T lymphocytes were more common in the stromal compartment of adenomyosis. This paper is centrally about adenomyosis—specifically aberrant Fgl-1 and Lag-3 expression in eutopic and ectopic endometrial tissue and associated stromal T-lymphocyte distribution in adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

adenomyosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (25)

Source provenance

europepmc
last seen: 2026-06-11T06:38:44.028908+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK